Fundz

INmune Bio Inc. Secures $4.5 Million in Recent Funding

PUBLIC · INMBOct 29, 2026

Amount Raised

$4.5 Million

Round Type

Post-IPO Equity

Boca Raton

Description

On October 27, 2026, INmune Bio Inc. entered into a securities purchase agreement to issue and sell 3,000,000 shares of common stock in a registered direct offering. The company expects to receive aggregate gross proceeds of $4.5 million from this offering. The funding will help support their ongoing research and development initiatives

Who to call at Inmune Bio, Inc., and when

A new round usually means Inmune Bio, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Inmune Bio, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Inmune Bio, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Inmune Bio, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Inmune Bio, Inc.

Location

1224 PROSPECT STREET

Boca Raton, Florida, United States

About

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (QuellorTM), cancer (INB03TM), Alzheimer's and Treatment Resistant Depression (XPro1595), and NASH (LIVNateTM). The Natural Killer Cell Priming Platform includes INKmuneTM aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Inmune Bio, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Inmune Bio, Inc.'s next move

See what Strategic adds

Inmune Bio, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.